Cancer Immunology, Immunotherapy

, Volume 64, Issue 1, pp 105–112 | Cite as

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

  • Luana Calabrò
  • Giovanni Luca Ceresoli
  • Alessandra di Pietro
  • Ornella Cutaia
  • Aldo Morra
  • Ramy Ibrahim
  • Michele Maio
Focussed Research Review

Abstract

No second-line treatment significantly prolongs the survival of malignant mesothelioma patients who have a high unmet medical need. Here, we comment on the therapeutic potential of cytotoxic T-lymphocyte-associated protein (CTLA)4-blockade by the anti-CTLA4 monoclonal antibody (mAb) tremelimumab of refractory malignant mesothelioma patients. We also focus on the critical role of an accurate tumor assessment in the course of treatment with immunomodulating mAb. Finally, treatment with potentially effective, second-generation checkpoint(s) inhibiting mAb, as well future combination strategies in this deadly disease, will be discussed.

Keywords

Mesothelioma Anti-CTLA4 mAb Tremelimumab Immunotherapy NIBIT-2013 

Abbreviations

AUC

Area under the curve

CT

Computed tomography

CTLA4

Cytotoxic T-lymphocyte antigen4

DCR

Disease control rate

DHA

DNA hypomethylating agent

ICOS

Inducible costimulator

Ig

Immunoglobulin

Iv

Intravenous

mAb

Monoclonal antibody

MM

Malignant mesothelioma

MRI

Magnetic resonance imaging

OS

Overall survival

PD

Progressing disease

PD-1

Programmed cell death 1

PD-L1

Programmed cell death ligand 1

PD-L2

Programmed cell death ligand 2

RECIST

Response evaluation criteria in solid tumors

RR

Response rate

TTP

Time to progression

W

Week

Wks

Weeks

References

  1. 1.
    Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89:716–724PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Ceresoli GL, Gridelli C, Santoro A (2007) Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist 12:850–863PubMedCrossRefGoogle Scholar
  3. 3.
    Datta A, Smith R, Fiorentino F, Treasure T (2014) Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position. Thorax 69:194–197PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644PubMedCrossRefGoogle Scholar
  5. 5.
    Santoro A, O’Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 3:756–763PubMedCrossRefGoogle Scholar
  6. 6.
    Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30:2509–2515PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P (2013) Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 14:543–551PubMedCrossRefGoogle Scholar
  8. 8.
    Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A (2010) Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 36:24–32PubMedCrossRefGoogle Scholar
  9. 9.
    Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26:1698–1704PubMedCrossRefGoogle Scholar
  10. 10.
    Krug LM, Kindler H, Calvert H, VANTAGE 014 et al (2011) Vorinostat in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial. Eur J Cancer 47(Suppl 2):2–3CrossRefGoogle Scholar
  11. 11.
    Ceresoli GL, Zucali PA (2012) Anti-angiogenic therapies for malignant pleural mesothelioma. Expert Opin Investig Drugs 21:833–844PubMedCrossRefGoogle Scholar
  12. 12.
    Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A (2011) Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 72:73–77PubMedCrossRefGoogle Scholar
  13. 13.
    Busacca S, Sheaff M, Arthur K, Gray SG, O’Byrne KJ, Richard DJ, Soltermann A, Opitz I, Pass H, Harkin DP, Quinn JE, Fennell DA (2012) BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol 227:200–208PubMedCrossRefGoogle Scholar
  14. 14.
    Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I (2013) Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 5(208):208ra147PubMedCrossRefGoogle Scholar
  15. 15.
    Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M (2013) Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14:1104–1111PubMedCrossRefGoogle Scholar
  16. 16.
    Eggermont A, Kroemer G, Zitvogel L (2013) Immunotherapy and the concept of a clinical cure. Eur J Cancer 49:2965–2967PubMedCrossRefGoogle Scholar
  17. 17.
    Calabrò L, Danielli R, Sigalotti L, Maio M (2010) Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol 37(5):460–467PubMedCrossRefGoogle Scholar
  18. 18.
    Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30(17):2046–2054PubMedCrossRefGoogle Scholar
  19. 19.
    Calabrò L, Maio M (2014) Immune checkpoint blockade in malignant mesothelioma: a novel therapeutic strategy against a deadly disease? OncoImmunology 3:e27482PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immunotherapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420PubMedCrossRefGoogle Scholar
  21. 21.
    Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257–260PubMedCrossRefGoogle Scholar
  22. 22.
    Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M (2012) Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 75(3):360–367PubMedCrossRefGoogle Scholar
  23. 23.
    Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, Biagioli M, Altomonte M, Maio M (2013) Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 62:1021–1028PubMedCrossRefGoogle Scholar
  24. 24.
    Calabrò L, Maio M (2014) Biomarkers for immune checkpoint inhibitors. Lancet Oncol 15(1):e1–e2PubMedCrossRefGoogle Scholar
  25. 25.
    Calabro’ L, Morra A, Fonsatti F, Cutaia O, Fazio C, Danielli D, Giannarelli D, Altomonte M, Di Giacomo AM, Maio M (2014) A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. J Clin Oncol 32:5s (suppl: abstr 7531)Google Scholar
  26. 26.
    Maeda M, Nishimura Y, Kumagai N, Hayashi H, Hatayama T, Katoh M, Miyahara N, Yamamoto S, Hirastuka J, Otsuki T (2010) Dysregulation of the immune system caused by silica and asbestos. J Immunotoxicol 7(4):268–278PubMedCrossRefGoogle Scholar
  27. 27.
    Bograd AJ, Suzuki K, Vertes E, Colovos C, Morales EA, Sadelain M, Adusumilli PS (2011) Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 60(11):1509–1527PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31(5):616–622PubMedCrossRefGoogle Scholar
  29. 29.
    Kumagai-Takei N, Maeda M, Chen Y, Matsuzaki H, Lee S, Nishimura Y, Hiratsuka J, Otsuki T (2011) Asbestos induces reduction of tumor immunity. Clin Dev Immunol 2011:481439. doi:10.1155/2011/481439  PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Miller BH, Rosado-de-Christenson ML, Mason AC, Fleming MV, White CC, Krasna MJ (1996) Malignant pleural mesothelioma: radiologic–pathologic correlation. Radiographics 16:613–644PubMedCrossRefGoogle Scholar
  31. 31.
    Wang ZJ, Reddy GP, Gotway MB, Higgins CB, Jablons DM, Ramaswamy M, Hawkins RA, Webb WR (2004) Malignant pleural mesothelioma: evaluation with CT, MR imaging and PET. Radiographics 24:105–119PubMedCrossRefGoogle Scholar
  32. 32.
    Leung AN, Miller NL, Miller RR (1990) CT in differential diagnosis of diffuse pleural disease. AJR 154:487–492PubMedCrossRefGoogle Scholar
  33. 33.
    Boiselle PM, Patz EF Jr, Vining DJ, Weissleder R, Shepard JA, McLoud TC (1998) Imaging of mediastinal limph nodes: CT, MR and FDG-PET. Radiographics 18:1061–1069PubMedCrossRefGoogle Scholar
  34. 34.
    Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C (1999) Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR 172:1039–1047PubMedCrossRefGoogle Scholar
  35. 35.
    van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP (2004) Inadequacy of the RECIST criteria for the evaluation of response in patient with malignant pleural mesothelioma. Lung Cancer 43(1):63–69PubMedCrossRefGoogle Scholar
  36. 36.
    Armato SG 3rd, Ogarek JL, Starkey A, Vogelzang NJ, Kindler HL, Kocherginsky M, MacMahon H (2006) Variability in mesothelioma tumor response classification. AJR 186:1000–1006PubMedCrossRefGoogle Scholar
  37. 37.
    Mullard A (2013) New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 12:489–492PubMedCrossRefGoogle Scholar
  38. 38.
    Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133PubMedCrossRefGoogle Scholar
  39. 39.
    Chen YB, Mu CY, Huang JA (2012) Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 98(6):751–755PubMedGoogle Scholar
  40. 40.
    Pardoll D (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264PubMedCrossRefGoogle Scholar
  41. 41.
    Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res [Epub ahead of print]Google Scholar
  42. 42.
    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Sigalotti L, Fratta E, Coral S, Maio M (2014) Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther 142(3):339–350. doi:10.1016/j.pharmthera.2013.12.015 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Luana Calabrò
    • 1
  • Giovanni Luca Ceresoli
    • 2
  • Alessandra di Pietro
    • 3
  • Ornella Cutaia
    • 1
  • Aldo Morra
    • 4
  • Ramy Ibrahim
    • 5
  • Michele Maio
    • 1
  1. 1.Immunoterapia Oncologica, Dipartimento di Oncologia Medica, Istituto Toscano TumoriAzienda Ospedaliera Universitaria SeneseSienaItaly
  2. 2.Thoracic and GU Oncology UnitCliniche Humanitas GavazzeniBergamoItaly
  3. 3.Clinical Development Oncology-MedImmuneGaithersburgUSA
  4. 4.Department of RadiologyEuganea Medica Diagnostic CenterPaduaItaly
  5. 5.Clinical, Immuno-Oncology, Global Medicines DevelopmentAstraZenecaGaithersburgUSA

Personalised recommendations